Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Preliminary results
Quarterly results
Director departure
Appointed director
CC transcript
Auditor change

ONTO INNOVATION INC. (NANO) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/09/2019 GN Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
07/09/2019 GN Nanobiotix annonce la publication dans le Lancet Oncology des données de phase III dans le Sarcome des Tissus Mous pour NBTXR3 son produit premier d'une nouvelle classe
07/03/2019 GN MERGER ALERT – ORIT and NANO: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
07/01/2019 GN DNBF, RTEC, and SHRC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
07/01/2019 GN MERGER ALERT – DNBF, SHRC, and NANO: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
07/01/2019 GN Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
07/01/2019 GN Nanobiotix annonce une nouvelle équipe de direction à la suite de son autorisation de mise sur le marché européen
06/24/2019 GN SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Nanometrics Incorporated with Rudolph Technologies, Inc. is Fair to NANO Shareholders
06/24/2019 GN RUDOLPH TECHNOLOGIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger
06/04/2019 GN NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL
06/04/2019 GN Nanobiotix nomme un nouveau directeur médical à la suite de son autorisation de mise sur le marché européen
05/28/2019 GN Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare
05/28/2019 GN Nanobiotix annonce le lancement de Curadigm : une nouvelle plateforme de nanotechnologie dédiée à la santé
04/10/2019 GN Nanometrics to Announce First Quarter Financial Results on April 30, 2019
04/09/2019 GN NANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES
04/09/2019 GN NANOBIOTIX LEVE ENVIRON 29,5 MILLIONS D'EUROS DANS LE CADRE D'UN PLACEMENT D'ACTIONS ORDINAIRES NOUVELLES
04/08/2019 GN NANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING
04/08/2019 GN NANOBIOTIX LANCE UNE AUGMENTATION DE CAPITAL PAR CONSTRUCTION ACCELEREE D'UN LIVRE D'ORDRE
04/04/2019 GN Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval
04/04/2019 GN NANOBIOTIX ANNONCE LA TOUTE PREMIERE AUTORISATION DE MISE SUR LE MARCHÉ EUROPEEN D'UN RADIOENHANCER
04/02/2019 GN Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
04/02/2019 GN Efficacité de la combinaison NBTXR3 (premier produit de sa classe), radiothérapie et immunothérapie avec anti-PD-1 démontrée dans le cancer du Poumon résistant dans des modèles précliniques in vivo
03/26/2019 GN Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy